Who is eligible for clinical trial NCT07731880?

Participants must meet protocol criteria for Malignant Female Reproductive System Neoplasm. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07731880 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-05

Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers (NCT07731880)

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Fred Hutchinson Cancer Center

🩺 Plain-English Summary (8th-Grade Level)

This study is being done to determine how easy it is to use standard of care (SOC) surgical resections or biopsy for SmartMatch analysis to determine treatment options in advanced gynecological malignancies.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (5 items).

Location: Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Age ≥ 18 years
Histologically confirmed rare gynecologic malignancy, including but not limited to those listed
Metastatic or unresectable disease, OR disease for which additional systemic therapy is indicated
Fresh tumor tissue available from a SOC surgical procedure or biopsy that in the judgment of the treating team will yield adequate viable tumor for SmartMatch analysis
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Adequate organ function to receive systemic therapy as determined by the treating oncologist (protocol does not specify thresholds because therapy is not mandated)
Ability to understand and willingness to sign informed consent
Willingness to allow data abstraction from the electronic health record for study endpoints

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Lack of tumor tissue suitable for SmartMatch analysis
Purely borderline tumors or benign ovarian/uterine neoplasms
Any condition that, in the opinion of the treating oncologist or PI, would interfere with receiving systemic therapy
Inability to provide informed consent or comply with study procedures

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗